# Limited evidence of pseudoprogression following immune checkpoint inhibitor (ICI) therapy in glioblastoma

## TL;DR

This study found little evidence of pseudoprogression in glioblastoma patients treated with immune checkpoint inhibitors.

## Contribution

The study provides new insights into the rarity of pseudoprogression with ICI therapy in glioblastoma.

## Key findings

- No pseudoprogression was observed in 55 glioblastoma patients treated with ICI.
- Results were consistent across newly diagnosed and recurrent disease cases.

## Abstract

“Pseudoprogression” following immune checkpoint inhibitors (ICI) in glioblastoma is often considered in case of radiographic progression. To better characterize the frequency of this phenomenon in glioblastoma, we reviewed the imaging response characteristics of a total of 55 patients treated with ICI in the setting of recurrent (n = 45) or newly diagnosed (n = 10) disease. There was no evidence of pseudoprogression related to ICI-monotherapy in the entire cohort.